Nov 05, 2024 09:35 AM
CX DAILY
CX Daily: How AstraZeneca’s China Fraud Was About More Than Greed
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
In 2023, the Chinese market generated $5.9 billion in revenue for AstraZeneca, accounting for 13% of its total, making it the company’s second largest market overall
AstraZeneca /
Cover Story: How AstraZeneca’s China fraud was about more than greed
AstraZeneca Plc is facing a setback in China as a three-year crackdown on alleged medical insurance fraud intensifies, culminating in an investigation into Leon Wang, the company’s president for the country.
On Oct. 30, AstraZeneca confirmed that Wang was “cooperating with an ongoing investigation.” While the company did not give details, it said it would “fully cooperate” with the authorities.
Register to read this article for free.
Register
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
Share this article
Open WeChat and scan the QR code
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新